Squarepoint Ops LLC Has $6.67 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Squarepoint Ops LLC lifted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 286.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 149,717 shares of the company's stock after purchasing an additional 110,966 shares during the quarter. Squarepoint Ops LLC owned approximately 0.32% of Omnicell worth $6,665,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Two Sigma Investments LP increased its holdings in Omnicell by 44.2% in the 4th quarter. Two Sigma Investments LP now owns 141,738 shares of the company's stock valued at $6,310,000 after buying an additional 43,471 shares during the period. Toronto Dominion Bank acquired a new stake in shares of Omnicell during the 4th quarter valued at about $30,637,000. Point72 Hong Kong Ltd bought a new stake in Omnicell in the fourth quarter valued at about $101,000. ProShare Advisors LLC increased its stake in Omnicell by 44.5% in the fourth quarter. ProShare Advisors LLC now owns 13,766 shares of the company's stock valued at $613,000 after acquiring an additional 4,238 shares during the period. Finally, Quantedge Capital Pte Ltd acquired a new position in Omnicell in the fourth quarter worth about $3,366,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the topic of several analyst reports. Wells Fargo & Company reiterated an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday, May 20th. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Bank of America lifted their price objective on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $44.83.

Omnicell Price Performance

Shares of Omnicell stock traded down $0.24 during trading on Wednesday, reaching $29.37. The company's stock had a trading volume of 395,319 shares, compared to its average volume of 564,799. The stock has a 50-day moving average price of $30.70 and a two-hundred day moving average price of $38.41. The stock has a market capitalization of $1.38 billion, a P/E ratio of 108.78, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The company had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.03 earnings per share. As a group, sell-side analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.